Erratum: Rethinking Early Intervention in Relapsing Multiple Sclerosis: A Closer Look at Long-Term Safety and Efficacy Data for a Sphingosine 1-Phosphate Receptor Modulator - European Medical Journal

This site is intended for healthcare professionals

Erratum: Rethinking Early Intervention in Relapsing Multiple Sclerosis: A Closer Look at Long-Term Safety and Efficacy Data for a Sphingosine 1-Phosphate Receptor Modulator

Neurology

Author:Jessica Jinks

Citation: Neurol AMJ. 2026; https://doi.org/10.33590/neurolamj/KK200SGN

Date correction published: 03/04/2026

Original publication¹

In the KOL interview article1 published on the AMJ website on January 22nd 2026, an error has been identified in Figure 3A. 

An error has been identified in Figure 3A of the published article. The four line markers and associated values above the bars were displayed in colours that did not correspond to the figure key. 

Figure 3A has been updated to ensure the colours align with the key and accurately represent the data. 

AMJ apologises for the error and any inconvenience caused. 

Reference:

1. Jinks J. Rethinking Early Intervention in Relapsing Multiple Sclerosis: A Closer Look at Long-Term Safety and Efficacy Data for a Sphingosine 1-Phosphate Receptor Modulator. Neurol AMJ. 2026;3[Suppl 1]:2-14. 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.